DMK Pharmaceuticals (DMK Pharmaceuticals) Accounts Payable & Accrued Expense : $9.97 Mil (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals Accounts Payable & Accrued Expense?

DMK Pharmaceuticals's quarterly accounts payable & accrued expense increased from Mar. 2023 ($11.61 Mil) to Jun. 2023 ($13.57 Mil) but then declined from Jun. 2023 ($13.57 Mil) to Sep. 2023 ($9.97 Mil).

DMK Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2020 ($4.49 Mil) to Dec. 2021 ($7.09 Mil) and increased from Dec. 2021 ($7.09 Mil) to Dec. 2022 ($9.45 Mil).

DMK Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for DMK Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Accounts Payable & Accrued Expense Chart

DMK Pharmaceuticals Annual Data

Trend

Mar13

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

7.93

6.70

4.49

7.09

9.45

DMK Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															6.64	9.45	11.61	13.57	9.97

DMK Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

0A4X:UK

Address

11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130

Website

https://www.adamispharmaceuticals.com

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Executives

Dorbin John W. Jr.	officer: General Counsel	C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen	officer: CFO	C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi	director, officer: CEO	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi	director	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed	director	TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio	director	2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd	director, 10 percent owner, officer: President/CEO	PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss	officer: Chief Medical Officer	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto	officer: Chief Financial Officer	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai	director	1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins	officer: Chief Financial Officer	2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels	officer: Vice President of Operations	11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf	director	C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams	director	26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134